Adalvo is pleased to announce the successful closure on the DCP procedure for our Icatibant development, a complex injectable peptide product, forming part of our high-value product portfolio offering to our partners.
Icatibant is an equivalent and more affordable version of Firazyr that will now be made more accessible to patients world-wide. The product is used to treat acute attacks of HAE. The development of this product was done in close collaboration with our strategic partner AmbioPharm, a global peptide manufacturer with one of the largest worldwide capacities.
Icatibant is truly a landmark product and this DCP registration procedure, which was submitted within almost all the EU region, proves our ability to bring complex high-value products to the market. With this achievement, we are among the first companies to get approval in all our major markets.
(Source: Adalvo)
